News | November 03, 2021
Sun Pharma Q2FY22 PAT jumps to Rs 2088.73 Cr
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The company has been sold to Shinshin Pharmaceuticals
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Subscribe To Our Newsletter & Stay Updated
